• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Relugolix combination therapy is efficacious for endometriosis-associated pain

byJessie WillisandTeddy Guo
June 30, 2022
in Chronic Disease, Obstetrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Relugolix combination therapy significantly reduced endometriosis-associated dysmenorrhea and non-menstrual pelvic pain compared to placebo.

2. Adverse events were similar between placebo and treatment, most common being headache, nasopharyngitis and hot flashes.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Limited options currently exist for treatment of endometriosis pain. Relugolix is an oral gonadotropin-releasing hormone receptor (GnRH) antagonist that may decrease pain in combination with estradiol and a progestin. These two duplicate phase 3 trials evaluated relugolix combination therapy for endometriosis pain. Eligible participants were randomized 1:1:1 to either placebo, relugolix combination therapy or delayed relugolix combination therapy for 24 weeks. Compared to placebo, relugolix combination therapy significantly reduced dysmenorrhea and non-menstrual pelvic pain after 24 weeks. Adverse events were similar between the placebo and treatment groups, with the most common being headache, nasopharyngitis and hot flashes. Reduction in bone mineral density and hot flashes were significantly more frequent in the delayed relugolix combination therapy compared to the relugolix combination therapy group. Limitations of this study include treatment duration limited to 6 months, particularly with the need to clinically monitor adverse outcomes such as reduced bone mineral density. Nevertheless, this study provides a promising option for the treatment of endometriosis-related pain.

Click to read the study in the Lancet

Relevant Reading: Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

In-Depth [randomized controlled trial]: This study reports the results of two replicate randomized trials, SPIRIT 1 and SPIRIT 2. Eligibility criteria included premenopausal women aged 18-50 years with endometriosis with moderate-to-very severe pain rated on the Endometriosis Associated Pain Severity score and a dysmenorrhea Numerical Rating Scale (NRS) of 4.0 or higher. Exclusion criteria included low bone mineral density or any contraindication to hormonal therapy. 638 women were randomized 1:1:1 to either placebo (n=213), relugolix combination therapy (n=212) or delayed relugolix combination therapy (n=213) in SPIRIT 1 and 623 women were randomized in SPIRIT 2. Delayed combination therapy was relugolix 40 mg monotherapy for 12 weeks followed by relugolix combination therapy for 12 weeks for the purpose of measuring bone mineral density change. Treatment lasted 24 weeks in all groups. The primary endpoint was dysmenorrhea and non-menstrual pelvic pain on an NRS and analgesic usage. In SPIRIT 1, 158/212 (75%) of participants receiving relugolix combination met the dysmenorrhea responder criteria compared to 57/212 (27%) in the placebo group (treatment difference 47.6% [95% CI 39.3-56.0; p<0.0001). In SPIRIT 2, these numbers with similar (treatment difference 44.9% [36.2-53.5; p<0.0001). The most common adverse events were headache, nasopharyngitis, and hot flashes. Bone mineral density change in lumbar spine was –0.70% in placebo, 0.21% in combination therapy, and –2.0% in delayed combination group for SPIRIT 1. These were similar in SPIRIT 2.

RELATED REPORTS

Linzagolix significantly reduces heavy menstrual bleeding in women with uterine fibroids

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bone mineral densityendometriosisestrogengonadotropin-releasing hormone antagonistgonadotropin-releasing hormone receptor antagonistHot Flashesrelugolix
Previous Post

Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination

Next Post

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

RelatedReports

Simvastatin associated with slowed fibroid growth in mice
Chronic Disease

Linzagolix significantly reduces heavy menstrual bleeding in women with uterine fibroids

September 28, 2022
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

April 13, 2022
Repeat bone mineral density testing may not improve prediction of fracture outcomes
Chronic Disease

Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

April 5, 2022
Early language exposure is predictive of language skills and IQ in school-age children
Chronic Disease

Endometriosis associated with early natural menopause

January 24, 2022
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]

Few differences in location-stratified football-related concussions

APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact

Strict tobacco licensing laws linked to reduced adolescent smoking initiation

Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Childhood maltreatment may cause mental health problems
  • #VisualAbstract: Hydrochlorothiazide does not impact risk of kidney-stone recurrence
  • Metformin use may decrease risk of osteoarthritis development
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options